Effentora® for DyspnoeaFentanylbuccaltablet for the Relief of Episodic Dyspnoea in Cancer Patients; an open label, randomized, morphine-controlled, crossover, phase II Trial - EffenDys

niversitätsklinikum KoelnZentrum für Palliativmedizin0 个研究点目标入组 30 人开始时间: 2013年3月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients with cancer suffering from episodes of dyspnoea (ED), inpatients only
•Principal inclusion criteria:
•1.Histologically or cytologically proven cancer of any entity which is non-curable as judged by the referring physician or investigator
•2.To be an inpatient during the study
•3.Refractory dyspnoea – this study applies only to ‘refractory dyspnoea’ and is defined: a patient is still dyspnoic although the underlying disease (e.g. lung cancer) or cause of dyspnoea (e.g. pleural effusion) is treated optimal as judged by the referring physician or investigator
•4.History of recurrent ED - ED is defined as an increase in dyspnoea occurring intermittently in patients with or without underlying continuous dyspnoea
•5.Peak intensity of ED = 3 (NRS, 0-10)
•6.Opioid tolerance for at least one day – opioid tolerance is defined: patient who receive per day at least 30mg oral morphine, 15mg oral oxycodone, 4mg oral hydromorphone, 12µg/h transdermal fentanyl or an analgetic equivalent of a different opioid or a different routes of application
•7.Life expectancy of at least one month as judged by the referring physician or investigator

•Principal exclusion criteria:
•1.Uncontrolled dyspnoea (i.e. rapidly worsening dyspnoea requiring urgent medical or technical intervention)
•2.Uncotrolled performance status (i.e. rapid deterioriation of performance status)
•3.Consideration of any reason by the referring therapeutic team that the patient is not an appropriate participant of a clinical trial
•4.Respiratory depression or preconditions with risk of respiratory depression
•5.Acute abdomen or ileus (except sufficiently palliated chronic malignant bowl obstruction)
•6.Renal dysfunction with creatinine clearance (eGFR) calculated as less than 25 ml/minute
•7.Medical history of severe hepatic impairment
•8.The use of fentanyl transmucosal products for breakthrough cancer pain (BTCP) during the trial
•9.The use of a monoamine oxidase inhibitors within the previous 14 days
•10.Treatment with any other investigational drugs within the previous 10 days

发起方

niversitätsklinikum KoelnZentrum für Palliativmedizin